# A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

> **NCT03498716** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 2199 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Dose-dense Doxorubicin or dose-dense Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03498716
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-02
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-08-14
- **Target enrollment:** 2199 (ACTUAL)
- **Why stopped:** The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS crossed the pre-specified futility boundary of hazard ratio \> 1 in the Intent-to-Treat (ITT) population.
- **Last updated:** 2024-08-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03498716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03498716, "A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03498716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*